AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Case-Finding for Neurocognitive Disorders in Pavia

RecruitingNAAges 18 Years - anyAllIRCCS National Neurological Institute "C. Mondinoโ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Dementia is a global public health challenge with a heavy caregiving burden, impacting families, communities, and healthcare systems. It is a priority in healthcare planning, with focus on early diagnosis and ongoing support. This research project addresses the global public health challenge posed by dementia, focusing on early detection and comprehensive care. The research evaluates the clinical, social, and healthcare impact of two dementia-related projects in Italy: 1. the first "Ricor-Dare," aims to create an integrated network for identifying new cases of dementia or Mild Cognitive Impairment (MCI) and providing care to patients and caregivers; 2. the second involves establishing a new Center for Cognitive Disorders and Dementia (CCDD) in an area previously lacking such services. The primary goal of this study is to assess the effectiveness of case-finding strategies promoted by t

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
For the Primary Outcome the inclusion criteria are: * Age 50 or older * Assessment conducted using GPcog/ACE-III depending on the setting * No prior diagnosis of cognitive decline * Ability to understand the study objectives and sign an informed consent For the Primary Outcome the exclusion criteria are: * Age under 50 * Presence of a diagnosis of cognitive decline * Limited knowledge of the Italian language For the secondary outcome the inclusion criteria are: Patient: * All patients/people who are included in one of the actions provided through the "Ricor-Dare" Project or who are attending a visit scheduled in the clinical-care pathway of the CDCD Fondazione Mondino Pavia or Lomellina; * Ability to understand the aims of the study and to sign an informed consent Caregiver: * Age equal to or greater than 18 years * Informal caregiver of a family member with a suspected or confirmed diagnosis of dementia who is included in one of the actions provided through the "Ricor-Dare" project or who are attending a visit scheduled in the clinical-care pathway of the CDCD; * Acceptance of informed consent and voluntary participation in the study. Healthcare professionals: * All healthcare and social healthcare professionals (GPs, pharmacists, nurses, nurses auxiliary) who practice in the cities of Pavia and Vigevano who participate in the project and agree to undergo assessments and training; * Acceptance of informed consent and voluntary participation in the study. Fo the Secondary Outcome the exclusion criteria are: Patient: \- Inability to understand the aims of the study and to sign an informed consent Caregiver: * Age under 18 * Formal caregivers, i.e. any person who provides assistance to the patient in exchange for payment of a fee; * Caregivers with limited knowledge of the Italian language.
๐Ÿ’Š

What it tests

  • Case-finding for Neurocognitive Disorders
๐Ÿ“

Where

1 site
IRCCS National Neurological Institute "C. Mondino" Foundation
Pavia, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy